Welcome to the world of enterprise. But note that what you call bias is in availability, not in publication. My conjecture is that this availability advantage accrues to wealthy universities and authors as well. Are you suggesting that this particular advantage of wealth be restricted or regulated? For all wealthy sources, or just drug companies? Or are you merely pointing out that this is a side